Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Marandino, 2019, Erdafitinib for the treatment of urothelial cancer, Expert Rev Anticancer Ther, 19, 835, 10.1080/14737140.2019.1671190 BALVERSA® (prescribing information). Horsham, PA: Janssen Products, LP; 2020. Loriot, 2019, Erdafitinib in locally advanced or metastatic urothelial carcinoma, N Engl J Med, 381, 338, 10.1056/NEJMoa1817323 Facchinetti, 2020, Facts and new hopes on selective FGFR inhibitors in solid tumors, Clin Cancer Res, 26, 764, 10.1158/1078-0432.CCR-19-2035 Schuler, 2019, Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study, Lancet Oncol, 20, 1454, 10.1016/S1470-2045(19)30412-7 Mazzaferro, 2019, Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma, Br J Cancer, 120, 165, 10.1038/s41416-018-0334-0 Javle, 2018, Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma, J Clin Oncol, 36, 276, 10.1200/JCO.2017.75.5009 Abou-Alfa, 2020, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Lancet Oncol, 21, 671, 10.1016/S1470-2045(20)30109-1 Siefker-Radtke, 2022, Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study, Lancet Oncol, 23, 248, 10.1016/S1470-2045(21)00660-4 Takeshita, 2018, Central role of the proximal tubular alphaKlotho/FGF receptor complex in FGF23-regulated phosphate and vitamin D metabolism, Sci Rep, 8, 6917, 10.1038/s41598-018-25087-3 Chae, 2017, Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application, Oncotarget, 8, 16052, 10.18632/oncotarget.14109 Tabernero, 2015, Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors, J Clin Oncol, 33, 3401, 10.1200/JCO.2014.60.7341 Lyou, 2020, Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1–3 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3-altered advanced/metastatic urothelial carcinoma, Eur Urol, 78, 916, 10.1016/j.eururo.2020.08.002 Dhondup, 2017, Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure, Blood Purif, 43, 179, 10.1159/000452725 Griffith, 2022, Calciphylaxis cutis associated with fibroblast growth factor receptor (FGFR) inhibitor therapy: a new challenge, Cureus, 14, e21478 Carr, 2019, Metastatic calcinosis cutis associated with a selective FGFR inhibitor, JAMA Dermatol, 155, 122, 10.1001/jamadermatol.2018.4070 Su, 2014, Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models, Bone Res, 2, 14003, 10.1038/boneres.2014.3 Floege, 2015, The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial, Clin J Am Soc Nephrol, 10, 800, 10.2215/CJN.10221014 Nigwekar, 2018, Calciphylaxis, N Engl J Med, 379, 399 Lacouture, 2021, Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines, Oncologist, 26, e316, 10.1002/onco.13552 Puar, 2022, Hyperphosphatemic tumoral calcinosis with pemigatinib use, AACE Clin Case Rep, 8, 217, 10.1016/j.aace.2022.07.001 Urner-Bloch, 2014, Transient MEK inhibitor-associated retinopathy in metastatic melanoma, Ann Oncol, 25, 1437, 10.1093/annonc/mdu169